Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Coya Therapeutics, Inc. ( (COYA) ).
On May 12, 2026, Coya Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC that allows the company to offer and sell up to $30 million of its common stock through at-the-market offerings on the Nasdaq Capital Market. The shares will be issued under an existing shelf registration, with Leerink Partners acting as sales agent on a commercially reasonable efforts basis, subject to customary conditions, commissions, and the company’s right to suspend or terminate the arrangement at any time.
Under the agreement, Coya may also sell shares to Leerink Partners as principal or through negotiated transactions, paying the firm a 3% commission on gross proceeds and reimbursing specified expenses. The flexible structure gives Coya incremental access to equity capital to support its operations while providing investors with potential ongoing issuance over time, though the company is not obligated to sell any shares and the arrangement terminates once the full $30 million is placed or either party ends the deal.
The most recent analyst rating on (COYA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
The score is held down primarily by ongoing losses and persistent cash burn, alongside a weak technical trend (below major moving averages with negative MACD). Offsetting factors include a low-leverage balance sheet and constructive corporate milestones (Fast Track/IND progress and new financing), but valuation remains constrained by unprofitability.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a biotechnology company focused on developing therapeutic products in the pharmaceutical and life sciences sector. The company operates in the U.S. capital markets, using equity offerings such as common stock issuances to fund its research, development, and corporate activities.
Average Trading Volume: 136,087
Technical Sentiment Signal: Sell
Current Market Cap: $96.41M
For detailed information about COYA stock, go to TipRanks’ Stock Analysis page.